Biodexa Pharmaceuticals (BDRX) Stock News

Biodexa Pharmaceuticals (NASDAQ: BDRX) has announced a significant change in its American Depositary Receipts (ADR) ratio. The company will modify its ADR ratio from 1:10,000 (1 ADR representing 10,000 ordinary shares) to 1:100,000 (1 ADR representing 100,000 ordinary shares), effective July 31, 2025.

ADR holders will be required to exchange their existing ADRs at a ratio of 10:1, with JP Morgan Chase Bank managing the exchange process. This change will effectively function as a 1-for-10 reverse ADR split, though the company's ordinary shares will remain unaffected. The primary goal is to achieve compliance with Nasdaq's minimum bid price requirement of $1.00 per share.

Biodexa Pharmaceuticals (NASDAQ:BDRX) has filed a Clinical Trial Application (CTA) with the European Medicines Agency for its Phase 3 Serenta trial investigating eRapa in Familial Adenomatous Polyposis (FAP). The trial will initially cover clinical sites in Denmark, Germany, Netherlands, and Spain, with Italy to be added later.

The company has achieved several milestones for its eRapa program, including FDA Fast Track Designation, European Orphan Drug designation, and initiation of its first US clinical site. The program is supported by a $20 million grant from CPRIT. The Serenta trial (NCT06950385) is designed as a randomized, double-blind, placebo-controlled Phase 3 study, with European sites expected to begin enrollment in Q4 2025.

Biodexa Pharmaceuticals (NASDAQ: BDRX), a clinical stage biopharmaceutical company, announced that all resolutions proposed at its Annual General Meeting held on June 26, 2025, were successfully passed by shareholders. The company, which focuses on developing innovative treatments for diseases with unmet medical needs, has made the full text of the passed resolutions available on its corporate website under the investor relations section.

Biodexa Pharmaceuticals (NASDAQ:BDRX) has announced the activation of its first clinical study site for the Phase 3 Serenta trial, evaluating eRapa in patients with familial adenomatous polyposis (FAP). The trial (NCT06950385) is designed as a randomized, double-blind, placebo-controlled study and is now actively enrolling participants.

The program has received significant support, including $20 million in grant funding from CPRIT, Fast Track Designation, and a positive Type C Meeting. The company has also launched a dedicated website for patient information at serentatrial.com.

Biodexa Pharmaceuticals (NASDAQ: BDRX) has announced 'Serenta' as the brand name for its upcoming Phase 3 clinical study focusing on familial adenomatous polyposis (FAP). The company has launched a dedicated website, www.serentatrial.com, to provide resources and information for patients, caregivers, and healthcare professionals. The website includes details about the study's objectives, FAP background information, and will feature program updates. The study will evaluate eRapa as a treatment for FAP. Chief Medical Officer Gary Shangold emphasized the company's commitment to providing accessible information and engaging with the FAP community throughout the study's progression.

Biodexa Pharmaceuticals (NASDAQ: BDRX) held a General Meeting on June 11, 2025, where shareholders approved all four proposed resolutions. Two key outcomes were achieved: First, resolutions 1 and 4 will reduce the nominal (par) value per ordinary share, though the total number of outstanding shares remains unchanged. Second, resolutions 2 and 3 grant the Directors authority to allot ordinary shares on a non-pre-emptive basis, giving them more flexibility in share issuance. The full text of the resolutions is available on the company's website under corporate governance.

Biodexa Pharmaceuticals (NASDAQ: BDRX) has initiated a Phase 2 study of tolimidone for Type 1 Diabetes treatment, with the first patient now recruited. The Investigator Initiated Trial, conducted at the University of Alberta Diabetes Institute, will evaluate 12 patients across three dose groups. The study will measure C-peptide levels (insulin marker) and HbA1c (blood glucose marker) after three months compared to baseline, along with monitoring hyperglycemic events. Preclinical studies at the University of Alberta have shown promising results, identifying Lyn kinase as crucial for beta cell survival and proliferation. Notably, tolimidone demonstrated the ability to induce proliferation in beta cells from human cadavers, suggesting potential therapeutic applications.

Biodexa Pharmaceuticals (NASDAQ: BDRX) provided a shareholder update detailing its financial position and Phase 3 eRapa program progress. The company has $5.7M in cash, $4.4M in escrow for eRapa Phase 3, and access to $11.9M in undrawn CPRIT grants, with minimal debt of $0.5M. The eRapa Phase 3 program for FAP treatment is substantially funded and entering final implementation stages. The study will involve 168 patients in a 2:1 drug/placebo ratio across 30 US and European clinical sites. With 50.5B ordinary shares outstanding (equivalent to 5.05M ADSs) and a $1.06 ADS price, BDRX's market cap stands at $5.4M. The company projects sufficient working capital through Q1 2026.

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) has announced a General Meeting scheduled for June 11, 2025, at their Cardiff offices. The company is proposing four key resolutions: (1) subdivision of each issued ordinary share of £0.001 into one ordinary share of £0.00005 and 19 C deferred shares of £0.00005, (2) authorization for Directors to allot shares up to £476,954.10 nominal value until 2028 AGM, (3) empowerment of Directors to allot equity securities for cash without pre-emption rights, and (4) adoption of new articles of association.

The primary purpose of these resolutions is to lower the par value of ordinary shares and enable the company to issue shares above par value. Importantly, the company states that these changes will not affect the number of outstanding ordinary shares or American Depositary Shares.